一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 2024 年度独立董事述职报告 本人孙健，作为深圳华大智造科技股份有限公司（以下简称"公司"）的独 立董事，在 2024 年度，本人按照《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法规、规范性 文件，以及《公司章程》和《独立董事工作制度》等公司内部制度的相关规定， 忠实勤勉履行职责，在董事会日常工作及重要决策中尽职尽责，从公司整体利益 出发，发挥了独立董事的应有作用，维护了公司和全体股东特别是中小股东的合 法权益。现将 2024 年度履行独立董事职责工作情况汇报如下： 本人的基本情况如下：孙健，男，1982 年出生，无境外居留权。2009 年 6 月毕业于中国人民大学商学院，获得会计学博士学位，2017 年获评会计学教授， 2019 年获评博士生导师。2009 年 7 月开始任教于中央财经大学会计学院，历任 会计学实验室主任、会计信息系主任、会计学院副院长。2015 年起，先后担任 熊猫金控股份有限公司、方正证券承销保荐有限公司、思享无限控股有限公司、 北京英诺特生物技术股份有限公司 ...

Financial Performance - The company reported a net profit of -191.39 million RMB for the parent company and -1.06226 billion RMB for the consolidated statements as of December 31, 2024, indicating negative retained earnings[4]. - The board has decided not to distribute profits for the year 2024 due to negative net profit and retained earnings[4]. - The company has not achieved profitability since its listing, as confirmed in the report[3]. - The net profit attributable to shareholders for 2024 was -CNY 600,827,020.56, showing a slight improvement from -CNY 607,499,880.61 in 2023[24]. - The net cash flow from operating activities for 2024 was -CNY 774,401,067.75, an improvement from -CNY 870,081,127.03 in 2023[24]. - The basic earnings per share for 2024 was -CNY 1.46, unchanged from 2023[25]. Revenue and Growth - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion in Q3 2023[13]. - The company's operating revenue for 2024 was CNY 3,012,531,769.09, representing a 3.48% increase compared to CNY 2,911,222,301.98 in 2023[24]. - The company achieved a main business revenue of 2,956.885 million yuan, with the gene sequencing instrument segment generating 2,347.8772 million yuan, a year-on-year increase of 2.47%[37]. - The laboratory automation segment generated revenue of 209.3691 million yuan, showing a significant growth of 36.69% compared to 2023[37]. - New business revenue amounted to 399.6386 million yuan, representing a year-on-year growth of 57.05% compared to 2023[37]. Operational Efficiency and Investments - The company is investing $50 million in new technology development to improve operational efficiency[14]. - The gross margin improved to 60%, up from 55% in the previous quarter, reflecting better cost management[14]. - The company plans to increase its workforce by 15% to support growth initiatives and new product development[14]. - The company has invested CNY 811.01 million in R&D, accounting for 26.92% of its revenue, to enhance innovation and ensure long-term sustainable development[55]. Research and Development - The R&D expenditure as a percentage of operating revenue was 26.92% in 2024, down from 31.26% in 2023, a decrease of 4.34 percentage points[25]. - The company has applied for 516 new patents and software copyrights, with 296 granted, including 139 invention patents, covering key areas in life sciences[55]. - The company has developed multiple core technologies in gene sequencing, including DNBSEQ sequencing technology and various library preparation techniques[185]. Product Development and Innovation - New product launches included a next-generation sequencing technology that is expected to enhance data accuracy by 30%[14]. - The company launched the new generation sequencing reagent StandardMPS 2.0, achieving ultra-high accuracy with Q40 quality, setting a new industry standard for sequencing data quality[40]. - The DNBSEQ-E25 Flash sequencing instrument can complete single-end 50bp sequencing in just 2 hours, significantly enhancing sequencing speed and meeting urgent public health response needs[41]. - The company has launched new products in the field of multi-omics, including MGIEasy tissue preservation solution and MGIDS-1000 enzyme-directed evolution screening system, enhancing sample preservation and enzyme screening efficiency[50]. Market Expansion and Strategy - The company is expanding its market presence in Asia, targeting a 20% increase in market share by the end of 2024[14]. - The company has established a global presence with 9 R&D centers, 7 production bases, and 9 international spare parts warehouses to support local business development[36]. - The company has expanded its global marketing network, covering 74 countries and regions, serving over 1,030 customers[66]. Corporate Governance and Compliance - The audit report issued by KPMG was a standard unqualified opinion, ensuring the accuracy of the financial statements[4]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[6]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company has not disclosed any special arrangements for corporate governance[7]. Risks and Challenges - The company has outlined various operational risks in the report, which are detailed in the section on "Risk Factors"[3]. - The report includes a forward-looking statement risk declaration, cautioning investors about potential risks in future plans and strategies[5]. - The company faces challenges in achieving seamless integration of heterogeneous systems in laboratory automation, which requires overcoming significant technical barriers[153]. Industry Trends and Market Outlook - The global gene sequencing instrument and consumables market is projected to grow from approximately $2.8 billion in 2017 to about $4.8 billion by 2024, with a compound annual growth rate (CAGR) of approximately 8.1%[133]. - The gene sequencing industry is currently in a transitional phase towards precision medicine, with the market temporarily at a development plateau due to geopolitical factors and the complexity of sequencing processes[133]. - The demand for precision diagnosis services has surged, leading to a growing sensitivity to sequencing costs among downstream applications[170].

Financial Performance - The company's operating revenue for Q1 2025 was ¥455,069,160.75, a decrease of 14.26% compared to ¥530,735,953.60 in the same period last year[4] - The net profit attributable to shareholders was -¥133,310,390.96, an improvement from -¥200,985,602.32 year-on-year[4] - The net cash flow from operating activities improved to -¥68,421,328.90 from -¥218,660,254.19 in the previous year[4] - Total revenue for Q1 2025 was CNY 455,069,160.75, a decrease of 14.2% compared to CNY 530,735,953.60 in Q1 2024[20] - Net loss for Q1 2025 was CNY 133,560,304.40, compared to a net loss of CNY 202,266,586.67 in Q1 2024, representing a 33.9% improvement[21] - Operating cash flow for Q1 2025 was negative CNY 68,421,328.90, an improvement from negative CNY 218,660,254.19 in Q1 2024[23] Research and Development - Research and development expenses totaled ¥168,648,860.34, down 16.70% from ¥202,456,558.64, representing 37.06% of operating revenue[5] - Research and development expenses decreased to CNY 136,094,352.68 in Q1 2025 from CNY 202,456,558.64 in Q1 2024, a reduction of 32.7%[20] - The company is focusing on core technology research and product innovation centered around gene sequencing technology to drive breakthroughs in scientific research and clinical applications[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,318,540,281.30, a slight increase of 0.04% from ¥10,314,855,725.90 at the end of the previous year[5] - The total assets of the company stood at ¥10,318,540,281.30 as of March 31, 2025, compared to ¥10,314,855,725.90 at the end of 2024, indicating stability in asset levels[18] - Total liabilities increased to CNY 2,581,926,144.13 in the latest reporting period, up from CNY 2,423,155,396.08[19] - Non-current liabilities rose to CNY 1,190,828,893.04, compared to CNY 828,099,509.27 in the previous year, an increase of 43.8%[19] - The company's total equity decreased to CNY 7,736,614,137.17 from CNY 7,891,700,329.82, reflecting a decline of 1.96%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,547[10] - The largest shareholder, Shenzhen BGI Technology Holdings Co., Ltd., held 36.73% of the shares[10] Cash Flow and Investments - As of March 31, 2025, the company's cash and cash equivalents increased to ¥2,754,139,448.44 from ¥2,283,525,148.87 as of December 31, 2024, reflecting a growth of approximately 20.6%[17] - The company received government subsidies amounting to ¥9,858,290.41 during the reporting period[6] - The net increase in cash and cash equivalents was $777,783,956.57, compared to a decrease of $551,909,550.96 in the prior period[24] - Cash inflow from financing activities totaled $413,160,000.00, with a net cash flow of $391,271,865.42, reflecting a decrease of $164,914,658.24[24] - Cash received from other investment activities was $2,518,000,000.00, contributing to the overall cash inflow[24] Product Launches - The company launched the DNBSEQ-AIO sequencing machine in January 2025, which automates the sequencing process and is designed for use in grassroots hospitals and local disease control centers[13] - In February 2025, the DNBSEQ-E25 Flash sequencing instrument was introduced, achieving a base calling speed of 25 seconds per cycle and capable of completing monkeypox virus genome sequencing in as little as 9 hours[14] - The α Cube data center machine was launched in March 2025, featuring high-performance computing capabilities and a modular architecture for various applications in bioinformatics[15] - The MGISTP-B1000 system was introduced for precise blood sample processing, enhancing efficiency in various applications including disease prevention and clinical testing[16] Cost Management - The company implemented a "cost reduction and efficiency enhancement" strategy, leading to a decrease in personnel and material costs[8]

证券代码：688114 证券简称：华大智造 公告编号：2025-029 深圳华大智造科技股份有限公司 关于变更会计政策的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示： 本次会计政策变更系根据中华人民共和国财政部（以下简称"财政部"）发 布的《企业会计准则解释第 17 号》及《企业会计准则解释第 18 号》的相关规 定进行的相应变更，无需提交公司董事会和股东大会审议，不会对公司财务状 况、经营成果和现金流量产生重大影响。 一、本次会计政策变更概述 （一）会计政策变更的主要内容 2023 年 10 月，财政部发布《企业会计准则解释第 17 号》（财会〔2023〕 21 号），规定了"关于流动负债与非流动负债的划分""关于供应商融资安排的 披露""关于售后租回交易的会计处理"的相关内容，该解释规定自 2024 年 1 月 1 日起施行。 2024 年 12 月，财政部发布《企业会计准则解释第 18 号》（财会〔2024〕 24 号），规定对不属于单项履约义务的保证类质量保证产生的预计负债，应当 按确定的金额计入"主 ...

毕马威华振 2023 年上市公司年报审计客户家数为 98 家，上市公司财务报 表审计收费总额约为人民币 5.38 亿元。表审计收费总额约为人民币 5.38 亿元。 这些上市公司主要行业涉及制造业，金融业，信息传输、软件和信息技术服务 业，电力、热力、燃气及水生产和供应业，交通运输、仓储和邮政业，批发和 零售业，采矿业，房地产业，科学研究和技术服务业，农、林、牧、渔业，租 深圳华大智造科技股份有限公司 2024 年度会计师事务所履职情况评估报告 深圳华大智造科技股份有限公司（以下简称"公司"）聘毕马威华振会计 师事务所（特殊普通合伙）（以下简称"毕马威华振"）作为公司 2024 年度财 务及内部控制审计机构。根据《国有企业、上市公司选聘会计师事务所管理办 法》，公司对毕马威华振 2024 年审计过程中的履职情况进行评估。经评估，公 司认为毕马威华振资质等方面合规有效，履职保持独立性，勤勉尽责，公允表 达意见，具体情况如下： 一、 会计师事务所基本情况 毕马威华振会计师事务所于 1992 年 8 月 18 日在北京成立，于 2012 年 7 月 5 日获财政部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振会 ...

深圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"）于 2025 年 4 月 28 日召开第二届董事会第十三次会议，审议通过了《关于续聘公司 2025 年度财务报告及内部控制审计机构的议案》。公司拟续聘毕马威华振会计师事务 所（特殊普通合伙）（以下简称"毕马威华振"）为本公司 2025 年度财务报告及 内部控制审计机构。该议案尚需提交公司股东大会审议。现将相关事项公告如下： 证券代码：688114 证券简称：华大智造 公告编号：2025-027 深圳华大智造科技股份有限公司 关于续聘公司 2025 年度财务报告及内部控制审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：毕马威华振会计师事务所（特殊普通合伙） 于 2024 年 12 月 31 日，毕马威华振有合伙人 241 人，注册会计师 1,309 人， 其中签署过证券服务业务审计报告的注册会计师超过 300 人。 一、拟续聘会计师事务所的基本情况： 1 （一） 机构信息 1、基本信息 毕马威华振总所位于 ...

以上授信额度不等于公司的实际融资金额，具体融资金额将视公司运营资金 的实际需求来合理确定，具体融资的种类、金额、利率、融资期限等以签署的具 体合同为准。 授信额度有效期为自本次董事会审议通过之日起至下一年度审议年度授信 额度的董事会或股东大会决议通过之日，授信额度在有效期内可以滚动使用。 为提高效率，公司董事会同意授权总经理或其授权人士审批在上述综合授信 额度内的资产抵押、质押事项。同时董事会同意授权公司总经理或其授权人士代 表公司与银行等金融机构签署上述授信额度内的有关法律文件。 证券代码：688114 证券简称：华大智造 公告编号：2025-024 深圳华大智造科技股份有限公司 关于向金融机构申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第二届董事会第十三次会议，审议通过了《关于向金融机构申请综合授信 额度的议案》，具体情况如下： 为满足公司及子公司生产经营和发展的需要，公司及全资或控股子公司拟向 银行等金融 ...

公司代码：688114 公司简称：华大智造 深圳华大智造科技股份有限公司 2024年度内部控制评价报告 深圳华大智造科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下 简称企业内部控制规范体系），结合深圳华大智造科技股份有限公司（以下简称"公司"） 内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司2024年 12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制 进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、 监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对 报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息 真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性， 故仅能为实现上述目标提供 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-022 深圳华大智造科技股份有限公司 关于公司 2025 年度对外担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●被担保人包括青岛华大智造科技有限责任公司、青岛华大智造极创科技有 限公司、青岛华大智造普惠科技有限公司、武汉华大智造科技有限公司、深圳华 大智造生物电子科技有限公司、MGI Americas Inc.、Complete Genomics, Inc.等公 司合并报表范围内的全资子公司。 ●公司及子公司拟为子公司的金融机构授信等融资业务及与客户所签署销 售合同下的履约义务等提供总额不超过人民币 10,000 万元的担保额度。截至 2024 年 12 月 31 日，公司及子公司对外担保总额为 5,458 万元，全部为公司对公 司全资子公司及全资子公司之间提供的担保，公司无逾期及涉及诉讼的对外担保。 ●本次担保是否有反担保：否 ●本事项无需提交公司股东大会审议。 一、担保情况概述 为提高公司决策效率，公司董事会授权公司 ...

深圳华大智造科技股份有限公司 2024 年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会(以下简称"证监会")发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交易所 科创板上市公司自律监管规则适用指引第 1 号——规范运作》等相关规定，深圳华大智 造科技股份有限公司(以下简称"公司"或"本公司")就 2024 年度募集资金存放与实 际使用情况作如下专项报告： 一、募集资金基本情况 (一) 实际募集资金情况 2022 年 7 月 26 日，经中国证券监督管理委员会《关于同意深圳华大智造科技股份 有限公司首次公开发行股票注册的批复》(证监许可[2022]1638 号)核准，公司首次公开 发行每股面值人民币 1.00 元的人民币普通股(A 股)41,319,475 股，每股发行价格人民币 87.18 元，募集资金总额人民币 3,602,231,830.50 元，扣除与募集资金相关的发行费用总 计人民币 317,677,388.48 元(不含增值税)，募集资金净额为人民币 3,284,554,442.02 元。 毕马威华振会计师事务所(特殊普通 ...